Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;59(9):5830-3.
doi: 10.1128/AAC.04865-14. Epub 2015 Jun 22.

Case-control study of the risk factors for acquisition of Pseudomonas and Proteus species during tigecycline therapy

Ga Eun Park  1 , Cheol-In Kang  2 , Yu Mi Wi  3 , Jae-Hoon Ko  1 , Woo Joo Lee  1 , Ji Yong Lee  1 , Sun Young Cho  1 , Young Eun Ha  1 , Doo Ryeon Chung  1 , Kyong Ran Peck  1 , Jae-Hoon Song  1
Affiliations

Case-control study of the risk factors for acquisition of Pseudomonas and Proteus species during tigecycline therapy

Ga Eun Park et al. Antimicrob Agents Chemother. 2015 Sep.

Abstract

Tigecycline is an important agent in clinical practice because of its broad-spectrum activity. However, it has no activity against Pseudomonas or Proteus species. We conducted a case-control study to analyze risk factors for the acquisition of Pseudomonas or Proteus spp. during tigecycline therapy. Placement of suction drainage at infected wound sites, ICU stay, and neurologic disease were identified as independent risk factors for the acquisition of Pseudomonas and Proteus spp.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Doan TL, Fung HB, Mehta D, Riska PF. 2006. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 28:1079–1106. doi:10.1016/j.clinthera.2006.08.011. - DOI - PubMed
    1. Brust K, Evans A, Plemmons R. 2014. Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review. J Antimicrob Chemother 69:2606–2610. doi:10.1093/jac/dku189. - DOI - PubMed
    1. Nicolau DP. 2009. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother 10:1213–1222. doi:10.1517/14656560902900853. - DOI - PubMed
    1. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43:738–744. - PMC - PubMed
    1. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. 2003. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 47:400–404. doi:10.1128/AAC.47.1.400-404.2003. - DOI - PMC - PubMed